FDA guidance
Acromegaly: Developing Drugs for Treatment
FDA guidance · Draft · issued Jan 30, 2023
Key facts
| Title | Acromegaly: Developing Drugs for Treatment |
|---|---|
| Status | Draft |
| Issue date | Jan 30, 2023 |
| Center | Center for Drug Evaluation and Research |
| Issuing office | Center for Drug Evaluation and Research |
| Communication type | Guidance Document |
| Regulated product | Drugs |
| Docket number | FDA-2022-D-2658 |
| Comments close | Mar 31, 2023 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents